Testosterone and gonadotropins have been associated with cognitive decline in men and the modulation of b amyloid (Ab) metabolism. The relatively few studies that have investigated whether changes in one or a combination of these hormones influence Ab levels have focused primarily on plasma Ab 1-40 and not on the more pathogenic Ab 1-42 . Currently, no study has investigated whether these hormones are associated with an increase in brain amyloid deposition, ante mortem. Through the highly characterised Australian imaging, biomarkers and lifestyle study, we have determined the impact of these hormones on plasma Ab levels and brain amyloid burden (Pittsburgh compound B (PiB) retention). Spearman's rank correlation and linear regression analysis was carried out across the cohort and within subclassifications. Luteinizing hormone (LH) was the only variable shown, in the total cohort, to have a significant impact on plasma Ab 1-40 and Ab 1-42 levels (beta ¼ 0.163, Po0.001; beta ¼ 0.446, Po0.001). This held in subjective memory complainers (SMC) (Ab 1-40 ; beta ¼ 0.208, P ¼ 0.017; Ab 1-42 ; beta ¼ 0.215, P ¼ 0.017) but was absent in mild cognitive impairment (MCI) and Alzheimer's disease (AD) groups. In SMC, increased frequency of the APOE-e4 allele (beta ¼ 0.536, Po0.001) and increasing serum LH levels (beta ¼ 0.421, P ¼ 0.004) had a significant impact on PiB retention. Whereas in MCI, PiB retention was associated with increased APOE-e4 allele copy number (beta ¼ 0.674, Po0.001) and decreasing calculated free testosterone (beta ¼ À 0.303, P ¼ 0.043). These findings suggest a potential progressive involvement of LH and testosterone in the early preclinical stages of AD. Furthermore, these hormones should be considered while attempting to predict AD at these earliest stages of the disease.
INTRODUCTION
Hormonal changes due to the dysregulation of the hypothalamic pituitary gonadal axis during aging have been associated with cognitive impairment, the risk of developing dementia and in the pathogenesis of Alzheimer's disease (AD). The majority of studies that have examined the effect of hormonal changes and cognition in elderly men have reported a positive association between circulating, free available testosterone (not bound to either albumin or sex hormone binding globulin, SHBG) or bioavailable testosterone (free and albumin-bound), and cognition. 1, 2 In addition, several studies have reported that compared to controls, men with AD and other dementias have lower serum total testosterone levels. [3] [4] [5] [6] [7] Further evidence for a direct role of testosterone in AD pathology was provided by studies that have reported a reduction in the brain levels of testosterone with age and in men neuropathologically diagnosed with AD. 8, 9 Testosterone has been shown to have a number of neuroprotective effects, including the reduction of oxidative stress and inflammatory processes, reducing tau phosphorylation and b amyloid (Ab) production, all key events in AD pathogenesis. Cell culture studies indicate that testosterone can modulate Ab production 10 and protect against Ab-mediated neurotoxicity. 11, 12 Reductions in testosterone levels have been shown to be associated with increases in plasma Ab levels. [13] [14] [15] In addition, androgen depletion in a transgenic mouse model accelerates brain Ab deposition and impairs hippocampal-dependent behavioural performance. 16 Administering the more potent testosterone metabolite dihydrotestosterone to rodent models can reverse behavioural impairments and reduce brain amyloid burden. 16, 17 Taken together, these in vitro and in vivo studies suggest that, at the very least, the reduction in androgens during aging in males may contribute to the cognitive and neuropathological changes observed in AD.
Sex steroid production is under the control of complex feedback loops within the hypothalamic pituitary-gonadal axis that regulate the levels of the pituitary gonadotropins, follicle stimulating hormone (FSH) and luteinizing hormone (LH), in turn controlling oestrogen and testosterone levels. In menopause, the loss of negative feedback by oestrogen results in marked increases in serum levels of gonadotropins. 18, 19 Abrupt diminution of gonadal function is not characteristic of male aging, where rises in serum LH concentrations occur gradually over time, 20 with inverse correlation between calculated free testosterone (cFT) and LH present in older men. 21 It is now becoming apparent that the increase in gonadotropin levels during aging may contribute to AD pathogenesis. Compared to age-matched controls, serum levels of gonadotropins have been shown to increase in subjects with AD. [3] [4] [5] 22, 23 In addition, an increase in LH immunoreactivity in the pyramidal neurons of the AD brain compared with age-matched controls has been reported. 24 Coupled with the recent finding that LH modulates Ab protein precursor processing and Ab generation in vitro, and that gonadotropin-releasing hormone agonists decrease Ab levels in mouse brain, 25, 26 these findings suggest that age-related increases in gonadotropins are a physiologically relevant signal that potentially modulates neurodegeneration in the aging brain.
Although, low levels of testosterone and high levels of gonadotropins have been associated with cognitive decline in dementia cases in men, 3, 4, 22, 23 there have been relatively few studies that have determined if changes in one or a combination of these hormones can influence plasma Ab levels. We provided the first clinical evidence that testosterone can regulate Ab levels in vivo by showing that a reduction in testosterone levels was associated with increased plasma Ab levels in dementia cases and in men that had undergone hormonal suppressive therapy for prostate cancer with flutamide or leuprolide. [13] [14] [15] We have also published findings showing that serum levels of LH were positively correlated with plasma Ab 1-40 levels in a group of cognitively normal elderly men. 27 Levels of free bioavailable testosterone were also strongly correlated with plasma Ab in cognitively normal men, however after controlling for the other covariates, testosterone was not shown to have an impact on plasma Ab 1-40 levels. This lack of association with testosterone may have been due to the small sample size (n ¼ 40). In addition, our previous study's analysis was limited to plasma Ab and was focused on associations between plasma Ab in cognitively normal controls or those individuals with AD. We further extend these studies in a larger, highly characterised cohort (n ¼ 427), where levels of plasma Ab and Ab are available. In addition, a subgroup of males (n ¼ 118) underwent PiB-PET (PiB positron emission topography) imaging to provide a measure of brain amyloid burden ante-mortem, and to investigate whether changes in testosterone or gonadotropins can influence brain amyloid burden.
PATIENTS AND METHODS
The AIBL cohort selection criteria and clinical assessments This study reports on data from 427 male individuals drawn from the AIBL (Australian imaging, biomarkers and lifestyle) cohort. The male participants consisted of 151 HC, 150 with subjective memory complaints (SMC), 50 individuals with mild cognitive impairment (MCI) and 76 with AD. Age and global cognitive status (as assessed by the mini mental-state examination) is presented in Table 1 . A full description of the cohort recruitment process, as well as the neuropsychological, cognitive and mood assessments, has been previously published. 28 The institutional ethics committees of Austin Health, St Vincent's Health, Hollywood Private Hospital and Edith Cowan University granted ethics approval for the AIBL study. All volunteers gave written informed consent before participating in the study.
Biochemistry
Baseline blood samples were taken and fractionated, with one aliquot sent to clinical pathology laboratories in Perth and Melbourne, as described previously. 28 SHBG levels were only available, from the clinical pathology laboratories, in a subset of individuals. However, SHBG levels were also available in all individuals through the data generated by Rules Based Medicine (Austin, TX, USA). Comparisons between both methods revealed no differences (SHBG-RBM, 57.98±33.50; SHBG-PathWest, 57.87±33.23; Paired T-Test, P ¼ 0.916). Isoforms of Ab were measured in plasma using a double sandwich ELISA technique, which has been well documented elsewhere. [29] [30] [31] Brain imaging A total of 118 (32 HC, 43 SMC, 24 MCI and 19 AD) of the 427 male participants (27.6%) in this study underwent PiB-PET imaging using the methodology described previously. 32, 33 Three-dimensional T1 MPRAGE and a T2 turbospin echo and FLAIR sequence MRI was acquired for screening and coregistration with the PET images. PET-standardized uptake value (SUV) data acquired 40-70 min post 11 PiB injections were summed and normalised to the cerebellar cortex SUV, resulting in a region to cerebellar ratio termed the SUV ratio (SUVR). PiB-PET was undertaken on a subset of 118 male participants (HC, n ¼ 32; SMC, n ¼ 43; MCI, n ¼ 24; AD, n ¼ 19).
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Statistical analysis
All variables were assessed for conformation to a normal distribution. Variables departing from a normal distribution were corrected according to Box-Cox transformations; 34 in all cases, the calculated l equated to notransformation or a natural logarithm (ln) transformation (indicated in text). Where values below 1 existed, a ln(x þ 1) transformation was applied (indicated in text). Initial analysis of variables was undertaken using the one-way analysis of variance to determine differences in continuous variables across clinical classifications with Tukey's honestly significant difference post-hoc analysis. Differences in categorical variables were determined using the w 2 -test. Correlations were performed using the Spearman's rank correlation test. Correction for the false discovery rate was undertaken in R (v2.15.1) 35 using Q-Value [36] [37] [38] [39] (bootstrap method for pi_0 with a lambda range of 0.0-0.95 by 0.1). Linear regression was undertaken to assess the associations between testosterone, gonadotropins, SHBG, plasma Ab isoform levels and ratios, PiB-PET SUVR and potential confounds such as age, BMI, insulin, thyroid stimulating hormone (TSH), free thyroxine, creatinine, current smoking and having been diagnosed with diabetes mellitus. All statistical analyses were conducted using Predictive Analytics Software Statistics (PASW Statistics, version 18.0.0; SPSS, Chicago, IL, USA) with the level of significance set to a ¼ 0.05 (two-tailed).
RESULTS
Baseline biological and demographic descriptive statistics for the 427 male participants are presented in Table 1 . A significant increase in the frequency of the APOE-e4 allele was seen across all clinical classifications, with AD and MCI individuals having a significantly higher frequency than HC and SMC (Po0.001). Analysis of plasma Ab isoforms and ratios revealed no significant differences across clinical classification. However, cerebral amyloid burden, as measured by PiB-PET imaging, revealed a clear differentiation of clinical classifications into three homogenous subsets: AD, MCI and SMC/HC (AD4SMC and HC, MCI4SMC and HC: Tukey's honestly significant difference, Po0.001 and Po0.01, respectively). Amyloid burden tended to be higher in AD individuals than in MCI, however this failed to reach statistical significance (Tukey's honestly significant difference, P ¼ 0.08).
Spearman's rank correlation analyses were first performed across the entire cohort (Supplementary Table 1 ). With respect to androgen and gonadotropin levels and their correlation with Ab isoforms and Ab burden, cFT was inversely correlated with Ab 1-42 (r s ¼ À 0.111, P ¼ 0.022, false discovery rate.corrected q-value ¼ 
Spearman's rank correlation analysis was also carried out within each respective clinical classification. In HC (Supplementary Table 2 ), no significant correlations between cFT and plasma Ab 1 À 40 , Ab or SUVR (Figures 1a and 2a) were observed. Likewise no correlations were observed with respect to gonadotropin levels. Linear regression revealed that in HC, elevated Ab levels were significantly correlated with the increasing copy number of the APOE-e4 allele (Ab 1 À 40 , beta ¼ 0.181, P ¼ 0.032; Ab 1-42 , beta ¼ 0.190, P ¼ 0.023), while SUVR was significantly correlated with the increasing copy number of the APOE-e4 allele (beta ¼ 0.417, P ¼ 0.019) and increasing age (beta ¼ 0.426, P ¼ 0.017). In SMC (Supplementary Table 3 Table 4) , cFT was not correlated with Ab levels (Figure 1c) , however, they were inversely correlated with SUVR (r s ¼ À 0.568, P ¼ 0.004, q-value ¼ 0.008; Figure 2c ). No correlation was observed for LH levels, however, FSH was positively correlated with SUVR (r s ¼ 0.493, P ¼ 0.014, qvalue ¼ 0.019). Linear regression analysis revealed that elevated Ab 1 À 40 levels significantly increased with LH levels (beta ¼ 0.388, P ¼ 0.005), but were inversely correlated with age (beta ¼ À 0.516, Po0.001), whereas Ab 1-42 levels were inversely correlated with both cFT levels (beta ¼ À 0.318, P ¼ 0.037) and age (beta ¼ À 0.380, P ¼ 0.014). Partial correlations between LH, cFT and plasma Ab, controlling for age, were undertaken in the upper and lower 50th percentiles for age in the MCI group, revealing only associations within the upper 50th percentile (LH/Ab 1 À 40 , r s ¼ 0.506, P ¼ 0.012; cFT/Ab 1 À 40 , r s ¼ À 0.418, P ¼ 0.042; cFT/Ab 1-42 , r s ¼ À 0.507, P ¼ 0.011). With respect to the increasing SUVR, linear regression analysis determined significant relationships with increasing copy number of the APOE-e4 allele (beta ¼ 0.674, Po0.001) and decreasing cFT (beta ¼ À 0.303, P ¼ 0.043). In AD individuals (Supplementary Table 5 ), no correlations were observed with respect to cFT, LH or FSH and likewise, all variables were dropped in linear regression analyses.
In MCI individuals (Supplementary

DISCUSSION
This study investigated whether changes in testosterone or gonadotropin serum levels were associated with plasma Ab and brain amyloid burden in a large, highly characterised cohort containing four clinical subgroups: HC, SMC, MCI and AD. 28 Regardless of clinical classification, age and the presence of the APOE-e4 allele had the expected significant impact on brain amyloid burden, whereas LH had a significant impact on plasma Ab 1 À 40 and Ab 1-42 levels. A closer examination within clinical subgroups revealed that both LH and cFT had a significant impact on both plasma Ab levels and brain amyloid burden in individuals clinically determined to be at the greatest risk of developing AD. Specifically, a progressive involvement of LH to cFT corresponded to the manifestation of objective clinical symptomology (that is, SMC to MCI).
In the absence of objective memory impairment, SMC has been shown to be a possible predictor of future cognitive decline. [40] [41] [42] Although, there is no evidence that suggests SMC alone is associated with increased dementia risk 43 in conjunction with APOE-e4, the risk of cognitive decline significantly increases. 44 Furthermore, we have recently reported that age and serum HDL levels were predictive for plasma Ab 1 À 40 levels in SMC. 45 These studies suggest that although SMC alone is not a predictor of dementia, when combined with other risk factors, it is potentially an early 'preclinical' marker of cognitive decline. In the current study, we present evidence in favour of this notion, by showing that changes in testosterone/gonadotropins can have an impact on plasma Ab and brain amyloid burden in SMC.
Regression analysis of the SMC cohort revealed that it accounted for the positive correlations of LH with plasma Ab 1 À 40 , Ab in the overall cohort. This association held after controlling for all covariates and was found, following analysis of the other clinical groups, to be limited to the SMC group only. These results agree with and further extend our previous findings in a small cohort of cognitively normal elderly men. 27 Although the male individuals in our previous study were cognitively normal, they were not categorised by memory complaints, and thus, the association may have been accounted by a higher percentage of SMC in the group that was analysed. The current study provides evidence that an association between LH and Ab 1 À 40 exists within the SMC, but not among non-memory complainers. Furthermore, this is the first study to show a similar impact of LH on plasma Ab 1-42 levels. While, the exogenous addition of LH to neuronal cells in culture results in the accumulation of Ab, and lowering the serum LH levels using the gonadotropin-releasing hormone agonist, leuprolide, lowers brain Ab burden, 25, 26 there is currently no evidence to suggest a direct impact of LH on Ab burden. Here, we show for the first time that, together with increasing age and APOE e4 carriage, a relationship exists between increasing LH levels and increases in brain amyloid burden. In recent animal studies, we have shown that the direct application of LH (or its more potent homologue, human chorionic gonadotropin) to the periphery of mice 46 or to the central nervous system of guinea pigs results in the accumulation of Ab in the brain. 47 Together with our results, these findings suggest that increases in LH have a direct impact on brain Ab burden, providing one mechanism by which LH could contribute to AD pathogenesis.
In the MCI group, LH and testosterone (together with age), were found to have an impact on different species of Ab. Both LH and testosterone have been shown to be associated with plasma Ab 1 À 40 levels. 13, 14, 27 Our previous findings have associated LH with plasma Ab 1 À 40 in cognitively normal men 27 and now we report this association in both SMC and MCI within the AIBL cohort. Surprisingly, in this analysis, cFT did not have a significant impact on plasma Ab 1 À 40 . It is difficult to reconcile the reason why, within the same group, LH and testosterone were correlated with plasma levels of different Ab species. Stratification of the MCI group by age, revealed the previously reported association between cFT and Ab 1 À 40 13, 14, 27 in the upper 50th percentile. Furthermore, the original associations between LH and Ab 1 À 40 and cFT and Ab held. No associations between hormones and Ab species were observed in the lower 50th percentile. These results suggest that the link between LH, cFT and Ab species is strongest in older MCI individuals conceivably most at risk of conversion to AD-this differential between old MCI and young MCI needs further longitudinal investigation to determine its validity.
Having established a relationship between LH, cFT and Ab in the periphery, we next investigated whether these relationships held for amyloid burden in the brain via PiB. In this cohort, we have previously shown that cortical PiB retention is markedly elevated in 98% of AD patients and 64% of participants with MCI. 48 Interestingly, 34% of cognitively normal controls showed abnormal cortical PiB retention. In addition, HC with subjective memory complaint carrying an APOE-e4 allele had significantly higher Ab burden than non-APOE-e4 carriers and non-complainers. 48 Our data extends these findings to show that in the SMC group, serum LH levels and APOE-e4 carrier status were the only variables studied where a relationship with changes in PiB-PET SUVR were seen. The APOE-e4 allele is known to have a major impact on brain amyloid deposition in AD. [49] [50] [51] [52] Evidence also exists that the APOE-e4 allele is associated with PiB cortical retention in cognitively normal people with a family history of AD. 53 Our current findings suggest that hormonal status together with PiB retention and other AD risk factors may be useful to predict those on the path to AD, prior to clinical symptomology. However, follow-up studies of this group, in addition to a larger cohort would be required to determine those that convert to MCI or clinical AD.
Although increases in serum LH were significantly associated with increased cortical PiB retention in the SMC group, this association was not present in the MCI or AD groups. Conversely, in the MCI group, cFT and the presence of the APOE-e4 allele had a significant impact on SUVR scores. These results suggest that although LH may have a more prominent role in promoting amyloid deposition in the brain prior to the onset of clinical symptoms, the impact of testosterone on Ab deposition is greater when clinical symptoms manifest. Our results also suggest that these hormones may have different roles in disease progression and this is influenced by a number of factors, including age and the presence of the APOE-e4 allele.
Using a highly characterised cohort, this study has for the first time reported associations between testosterone and LH with plasma Ab 1 À 40 and Ab 1-42 levels and cortical PiB retention. These associations occurred at preclinical (SMC) or at very early clinical (MCI) stages of AD and were lost with the onset of the disease, suggesting that that each of these hormones have an impact on AD pathogenesis at different times of the disease process. From a biological standpoint, this scenario can be likened to that of the increases in serum TSH levels and reductions in thyroid hormones, a diagnostic marker of underactive thyroid (hypothyroidism). The release of TSH from the anterior pituitary, acts on the thyroid to release thyroxine (T4) and triiodothyronine (T3). Similar to the mechanism of LH and testosterone regulation in the HPG axis, TSH and the thyroid hormones are regulated via a negative feedback loop. In the case of low thyroid hormone production due to an underactive thyroid (such as in hypothyroidism), serum levels of TSH will be high. In subclinical hypothyroidism, TSH levels are elevated whereas free T4 levels remain within the reference interval for the assay, as compared to progression to overt hypothyroidism when thyroid hormone levels fall below the assay reference interval and then, the symptoms manifest. 54 This analogy could be applied to our findings where elevated LH levels precede the fall in serum testosterone. Elevated LH levels are associated with increased plasma Ab levels and amyloid burden in SMC (prior to the onset of clinical symptoms), but the association is lost with the onset and severity of clinical symptoms (that is, MCI and AD). With the onset of objective clinical symptomology (that is, MCI), the reduced levels of testosterone are associated with a greater amyloid burden.
The associations between LH, testosterone and plasma Ab and PiB retention would need further validation in larger follow-up studies, to first determine those that convert from SMC to MCI and MCI to AD and then determine if testosterone or LH serum levels have a direct impact on plasma Ab ratio and cortical PiB retention in those that convert. Longitudinal follow-up of the AIBL cohort is currently underway. Our current results suggest a potential progressive involvement of LH and testosterone in the early preclinical stages of AD, and that, in conjunction with other known risk factors/biomarkers (established or candidate) of AD, hormonal levels should be considered when attempting to predict AD development at the earliest stages of the disease process.
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